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AbsTrACT
Objectives the ability to efficiently and accurately 
predict future risk of primary total hip and knee 
replacement (tHr/tKr) in earlier stages of osteoarthritis 
(oA) has potentially important applications. We aimed 
to develop and validate two models to estimate an 
individual’s risk of primary tHr and tKr in patients newly 
presenting to primary care.
Methods We identified two cohorts of patients aged 
≥40 years newly consulting hip pain/oA and knee pain/
oA in the Clinical practice research datalink. Candidate 
predictors were identified by systematic review, novel 
hypothesis-free ’record-Wide Association Study’ with 
replication, and panel consensus. Cox proportional 
hazards models accounting for competing risk of death 
were applied to derive risk algorithms for tHr and 
tKr. Internal–external cross-validation (IECV) was 
then applied over geographical regions to validate two 
models.
results 45 predictors for tHr and 53 for tKr were 
identified, reviewed and selected by the panel. 301 
052 and 416 030 patients newly consulting between 
1992 and 2015 were identified in the hip and knee 
cohorts, respectively (median follow-up 6 years). the 
resultant model C-statistics is 0.73 (0.72, 0.73) and 
0.79 (0.78, 0.79) for tHr (with 20 predictors) and 
tKr model (with 24 predictors), respectively. the IECV 
C-statistics ranged between 0.70–0.74 (tHr model) 
and 0.76–0.82 (tKr model); the IECV calibration 
slope ranged between 0.93–1.07 (tHr model) and 
0.92–1.12 (tKr model).
Conclusions two prediction models with good 
discrimination and calibration that estimate 
individuals’ risk of tHr and tKr have been developed 
and validated in large-scale, nationally representative 
data, and are readily automated in electronic patient 
records.
InTrOduCTIOn
Osteoarthritis (OA) is the most common form of 
arthritis and a leading cause of disability in popu-
lations worldwide.1 Although characterised as a 
slowly progressive condition, recent studies have 
highlighted substantial heterogeneity between 
groups of patients in the course of symptoms,2–4 
function5 and structural disease.6 Healthcare 
costs attributed to OA, driven largely by primary 
and revision arthroplasty,7 appear concentrated 
in a minority of patients.8 The development 
and application of prognostic models capable 
of identifying patients with OA at high risk of 
future progression is now recognised as a priority 
internationally and by patients, carers and health 
and social care professionals.9 Such models could 
have important clinical and research applica-
tions: better targeting of intensive non-surgical 
care; selection of patients for active monitoring; 
Key messages
What is already known about this subject?
 ► The majority of primary total hip replacement 
(THR) and primary total knee replacement 
(TKR) were performed for patients with end-
stage osteoarthritis in the UK, but clinical risk 
predictions of THR and TKR in patients who 
newly presenting hip pain/osteoarthritis and 
knee pain/osteoarthritis at the primary care 
settings have not been developed.
What does this study add?
 ► A novel approach for predictor selection has 
been developed. Two risk prediction models 
based on clinical variables that are available 
in the UK primary care electronic health record 
have been developed and validated. These 
algorithms can be used to inform clinical 
decision making, for example targeting 
intensive non-surgical management at patients 
identified at high risk of future primary THR or 
TKR.
How might this impact on clinical practice?
 ► These algorithms can be used to inform 
clinical decision making, for example targeting 
intensive non-surgical management at patients 
identified at high risk of future primary THR or 
TKR.
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timely assessment and discussion of appropriateness for 
referral and recruitment of ‘high-risk’ patients as part of effi-
cient clinical trial design evaluating new secondary preven-
tion treatments.
Models that rely on pooling data from existing clinical 
trials and bespoke cohorts may offer the prospect of carefully 
measured, highly relevant predictors and outcomes, but are 
limited by the availability of large, long-term studies with 
sufficient harmonised data. Furthermore, due to the high 
prevalence of OA and to time and cost constraints, models 
that require the collection of biomarkers, imaging or lengthy 
patient-reported instruments are unlikely to be implemented 
at scale in routine primary care, irrespective of their informa-
tiveness in research settings. An alternative approach, and the 
one chosen in our study, is to investigate whether data already 
routinely available in large, representative primary electronic 
healthcare databases could provide accurate predictions which 
are feasible for implementing in routine primary care. This 
approach has been used to derive and validate risk algorithms 
for condition-specific outcomes in other chronic non-com-
municable diseases and for complex events such as hospital 
admissions.10–18
We sought to develop and validate multivariable prediction 
models, based exclusively on information routinely recorded 
within the primary care electronic health record, to estimate 
the risk of primary total hip replacement (THR) and total knee 
replacement (TKR) in patients newly presenting with hip pain/
OA and knee pain/OA in UK primary care. To achieve this, 
we included a novel approach to identify candidate prognostic 
factors recorded in the primary care patient record.
MeTHOds
data source and study population
We used data from the Clinical Practice Research Datalink 
(CPRD) covering a representative sample of 7% of the UK 
general population.19 The definition20 and the selection of 
population were presented in online supplementary technical 
appendix, figures S1 and S2.
defining THr/TKr
Primary THR and TKR were identified within CPRD using the 
Read code list developed and applied in CPRD by Culliford 
and colleagues21 and validated by Hawley et al.22 23 Details of 
outcome definition was presented in online supplementary tech-
nical appendix.
Candidate predictors
Candidate predictors were identified from three sources: 
(i) a systematic review of previously published studies 
(further details available in online supplementary technical 
appendix); (ii) potentially relevant general predictors used 
within 12 QResearch risk algorithms and shown to be feasibly 
obtained from UK primary care (eg, sociodemographic, life-
style related, comorbidities)10–18 24–26 (iii) a hypothesis-free 
record-wide association study (ReWAS) of all third-level Read 
morbidity and process of care codes and for prescribed medi-
cine, third-level sections within the British National Formu-
lary which had been recorded in ≥1% of cases in the 3 years 
prior to date of arthroplasty. There were 6109 third-level 
Read morbidity and process of care codes and 325 prescribed 
medications assessed. The ReWAS case-control analysis was 
conducted in CPRD, with replication of ‘hits’ in a separate 
UK regional primary care Electronic Health Record (EHR) 
dataset—Consultations in Primary Care Archive (further 
details available in online supplementary technical appendix). 
Morbidities, processes of care and prescribed medications 
that were statistically significantly associated with THR or 
TKR in the screen were taken forward (online supplementary 
figures S3 and S5 for TKR; online supplementary figures S4 
and S6 for THR). The candidate predictors were assessed for 
clinical relevance by a review panel including seven members 
(six clinicians and one lay member), and the predictors agreed 
as relevant by ≥4 members were included in the modelling 
stage (online supplementary table S1). This process identi-
fied 29 candidate predictors for THR and 34 for TKR. These 
were extracted from records in the 3 years prior to index 
consultation.
statistical analysis for model derivation
Primary THR and TKR occurring since the patients’ index 
consultation for hip pain/OA and knee pain/OA in primary care 
were treated as time-to-event outcomes in the THR and TKR 
models, respectively. Statistical method of predictor selection 
was presented in online supplementary technical appendix.
We formed the risk (cumulative incidence) equations for 
predicting an individual’s 10-year probability of primary THR 
and TKR since the index consultation for hip pain/OA and knee 
pain/OA, by using the developed model’s baseline cumulative 
incidence function (CIF) at 10 years, along with the estimated 
regression coefficients (β) and the individual’s predictor values 
(X) using the following equation27:
 
�CIF (t = 10) = 1− (1−�CIF0(t = 10))exp(Xβ̂) 
Validation of prediction models
We assessed the model discrimination using Harrell’s C-statistic 
and the model calibration using calibration slope (details in 
online supplementary technical appendix)28–30 over the 10 years 
of follow-up.
We assessed the apparent performance of the models; that 
is, the observed performance in exactly the same data used to 
develop the model. However, we also used an internal–external 
cross-validation (IECV) approach (online supplementary tech-
nical appendix) to evaluate the two derived prediction models 
over 13 geographical regions in the UK (presented in table 1).31–33
Multiple imputation using chained equations was applied to 
handle missing values, and the imputation model included all 
candidate predictors and outcome (online supplementary tech-
nical appendix).34
Based on the 15 509 THRs and a total of 73 predictor param-
eters and 18 ,289 TKRs and 79 predictor parameters, we had an 
effective sample size of 212 events per predictor parameter for 
the THR derivation cohort and 232 events per predictor param-
eter for the TKR derivation cohort, above the minimum require-
ment suggested by Peduzzi.35
In a sensitivity analysis, we assessed the models’ performances 
when including patients with a THR and TKR within the first 
2 years after the index consultation (an exclusion criteria for 
the main analysis). In the other sensitivity analysis, we derived 
model coefficients by applying final predictors into patients with 
a THR and TKR within the first 2 years after the index consulta-
tion (an exclusion criteria for the main analysis).
We used Stata MP V.15.1 version for all statistical anal-
yses. This study was conducted and reported in line with the 
transparent reporting of a multivariable prediction model for 
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Table 1 Characteristics of study populations for the primary total 
knee replacement (TKR) model and primary total hip replacement 
(THR) models
Predictor
THr model TKr model
n=301 052 n=416 030
  Outcome, n (%) 15 509 (5.15) 18 289 (4.40)
  Median follow-up duration (range), 
years
6.27 (2.00 to 24.49) 6.21 (2.00 to 24.56)
  Gender (female) 191 288 (63.54) 238 549 (57.34)
Ethnicity 
  White 92 269 (30.65) 125 982 (30.28)
  Other ethnicity group 3621 (1.20) 6001 (1.44)
  Not recorded 205 162 (68.15) 284 047 (68.28)
Region 
  North East 6552 (2.18) 8647 (2.08)
  North West 38 618 (12.83) 51 331 (12.34)
  Yorkshire and the Humber 13 140 (4.36) 17 282 (4.15)
  East Midlands 12 779 (4.24) 16 670 (4.00)
  West Midlands 29 273 (9.72) 40 383 (9.71)
  East of England 26 194 (8.70) 36 488 (8.77)
  South West 24 885 (8.27) 34 216 (8.22)
  South Central 32 048 (10.65) 46 736 (11.32)
  London 23 541 (7.82) 35 197 (8.46)
  South East Coast 28 760 (9.55) 41 608 (10.00)
  Northern Ireland 11 445 (3.80) 14 708 (3.54)
  Scotland 25 672 (8.53) 34 547 (8.30)
  Wales 28 145 (9.35) 38 217 (9.18)
  Family history of arthritis/ 
osteoarthritis (OA)
1862 (0.62) 2135 (0.51)
Smoking status 
  Light smoker 6845 (2.27) 8502 (2.04)
  Moderate/heavy smoker 34 896 (11.59) 48 398 (11.63)
Drinking status 
  Ex-drinker 11 069 (3.68) 13 924 (3.35)
  Light drinker 212 058 (70.44) 294 273 (70.73)
  Moderate drinker 4172 (1.39) 6523 (1.57)
  Heavy drinker 1945 (0.65) 3177 (0.76)
Physical activity 
  Taking light physical activity 26 855 (8.92) 44 876 (10.53)
  Taking moderate physical activity 17 526 (5.82) 29 665 (7.13)
  Taking heavy physical activity 1984 (0.66) 3229 (0.78)
  Having diet consultation 110 780 (36.80) 173 969 (41.82)
  Asthma – 59 326 (14.26)
  COPD – 20 114 (4.83)
  Chronic liver disease 6962 (2.31) 10 798 (2.60)
  Diabetes mellitus 42 352 (14.07) 54 339 (13.06)
  Malabsorption 1488 (0.49) 2091 (0.50)
  Inflammatory bowel disease 16 863 (5.60) 26 722 (6.42)
  Dementia 1265 (0.42) 2710 (0.65)
  Cerebral palsy 153 (0.05) 205 (0.05)
  Multiple sclerosis 942 (0.31) 1280 (0.31)
  Cerebrovascular disease 11 819 (3.93) 16 150 (3.88)
Mental disorder 
  Anxiety 38 133 (12.67) 56 163 (13.50)
  Depression 48 558 (16.13) 36 034 (8.66)
  Rheumatoid arthritis 5031 (1.67) 10 200 (2.45)
  Systemic lupus erythematosus 673 (0.22) 865 (0.21)
  Falls 29 780 (9.89) 49 859 (11.98)
Continued
Predictor
THr model TKr model
n=301 052 n=416 030
  Previous hip injury for THR model/
previous knee injury for TKR model
7115 (2.36) 26 735 (6.43)
  Osteoporosis 12 953 (4.30) 19 481 (4.68)
  Knee effusion – 6243 (1.50)
  Diabetic foot 13 915 (4.62) –
  Bleed 44 812 (14.89) 70 543 (16.96)
  Scoliosis/kyphosis 2340 (0.78) 3292 (0.79)
  Development dysplasia of the hip 67 (0.02) 76 (0.02)
  Chondrocalcinosis 781 (0.26) 1588 (0.38)
Recorded diagnosis of joint-specific OA 
  Hip OA for TKR model/knee OA for 
THR model
272 (0.09) 26 640 (6.40)
  Hand OA 9897 (3.29) 12 419 (2.99)
  Generalised OA 7733 (2.57) 10 715 (2.58)
  Other joint OA 12 380 (4.11) 151 282 (3.64)
  Recorded diagnosis of non-specific OA 123 810 (41.13) 147 103 (35.36)
  Low back pain 150 759 (50.08) 218 702 (52.57)
  Hypertension 101 999 (33.88) 149 307 (35.89)
  Atrial fibrillation 9842 (3.27) 16 515 (3.97)
  Congestive cardiac failure 6397 (2.12) 9661 (2.32)
  Venous thromboembolism 8040 (2.67) 12 245 (2.94)
  Valvular heart disease 4157 (1.38) 6823 (1.64)
  Joint injection – 42 434 (10.20)
  Knee arthroscopy – 8310 (2.00)
  ACL reconstruction – 430 (0.10)
  Phenytoin 819 (0.27) 1248 (0.30)
  Physiotherapy 26 972 (8.96) 41 547 (9.99)
  Corticosteroids – 62 127 (14.93)
  Glucocosteroids 32 203 (10.70) 51 645 (12.41)
  Antidepressant 109 062 (36.23) 159 899 (38.43)
Analgesics 
  Weak combination opioids 192 249 (63.86) 268 421 (64.52)
  Moderate combination opioids 3231 (1.07) 4837 (1.16)
  Strong/very strong combination 
opioids
3034 (1.01) 6359 (1.53)
  Hormone treatment 82 221 (27.31) 107 321 (25.78)
  Bisphosphonates 15 249 (5.07) 24 147 (5.80)
Topical NSAIDS 
  NSAIDS 68 002 (22.59) 112 705 (27.09)
  Other 3627 (1.20) 7422 (1.78)
Drugs for rheumatoid disease and
gout 
  NSAIDS 183 107 (60.82) 268 850 (64.62)
  COX2 20 161 (6.70) 26 748 (6.43)
  Prostaglandins and oxytocics 10 359 (3.44) 15 837 (3.80)
  Rheumatoid factor test 876 (0.29) 1124 (0.27)
  Age, mean±SD, years 62.98±12.17 60.71±12.39
  Body mass index, mean±SD, kg/m2 27.70±5.44 28.06±5.62
  Charlson comorbidity index, median 
(nterquartile)
1 (0 to 2) 1 (0 to 2)
  Number of consultations, median 
(interquartile)
56 (0 to 111) 65 (32 to 113)
  Number of referrals, median 
(interquartile)
0 (0 to 1) 1 (0 to 1)
  Polypharmacy, median (interquartile) 7 (5 to 9) 6 (0 to 8)
  Missing information: body mass  
index
16 226 (5.39) 23 555 (5.66)
Table 1 Continued
Continued
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Predictor
THr model TKr model
n=301 052 n=416 030
ACL, anterior cruciate ligament; COPD, chronic obstructive pulmonary disease; 
COX2, cyclooxygenase-2; NSAIDS, non-steroidal anti-inflammatory drugs.
Table 1 Continued Table 2 Adjusted subdistribution hazard ratios and final model 
coefficients
Predictor
subdistribution 
hazard ratio (95 CI)
beta 
coefficient
Final model for primary total hip replacement
  Gender: women vs men 1.00 (0.96 to 1.04) 0.002179
Smoking status 
  Non-smoker/not recorded/ex-smoker reference
  Light smoker 0.64 (0.54 to 0.75) −0.446637
  Moderate/heavy smoker 0.75 (0.70 to 0.80) −0.283425
Drinking status 
  Non-drinker/not recorded reference
  Ex-drinker 1.01 (0.91 to 1.11) 0.008542
  Light drinker 1.18 (1.13 to 1.24) 0.167673
  Moderate drinker 1.36 (1.18 to 1.56) 0.304068
  Heavy drinker 1.06 (0.83, 1.36) 0.062211
  Diabetes mellitus: yes vs no 0.86 (0.81 to 0.91) −0.154314
Mental disorders: yes vs no 
  No/not recorded reference
  Anxiety 0.85 (0.80 to 0.90) −0.162867
  Depression 0.85 (0.80 to 0.90) −0.164488
  Falls 0.85 (0.80, 0.91) −0.157293
  Previous hip injury: yes vs no 1.54 (1.40 to 1.69) 0.432446
Recorded diagnosis of joint-specific osteoarthritis (OA) 
  No/not recorded reference
  Knee OA 1.02 (0.64 to 1.61) 0.015210
  Hand OA 0.21 (0.18 to 0.24) −1.582914
  Generalised OA 0.29 (0.25 to 0.33) −1.242895
  Other joint OA 0.23 (0.20 to 0.26) −1.473753
  Recorded diagnosis of non-specific OA: yes 
vs no
0.27 (0.26 to 0.28) −1.312229
Analgesics 
  No prescription reference
  Weak combination opioids 0.93 (0.89 to 0.97) −0.072075
  Moderate combination opioids 1.00 (0.85 to 1.19) 0.002597
  Strong/very strong combination opioids 1.06 (0.87 to 1.29) 0.056441
  Antidepressant: yes vs no 0.96 (0.92 to 1.01) −0.036091
Topical NSAIDS 
  No prescription reference
  NSAIDS 0.77 (0.73 to 0.80) −0.266746
  Other 0.78 (0.65 to 0.94) −0.247566
NSAIDS/COX2 
  No prescription reference
  NSAIDS 1.06 (1.02 to 1.10) 0.056447
  COX2 1.18 (1.10 to 1.26) 0.164306
  Hormone treatment: yes vs no 0.96 (0.92 to 1.01) −0.039146
  (Age/10)^3 – 0.056927
  (Age/10)^3*ln(age/10) – −0.024913
  (Body mass index (BMI)/10)^2 – 0.137871
  (BMI/10)^3 – −0.024987
  ((Charlson comorbidity index+1)/10)^−2 – 0.001583
  ((Charlson comorbidity index+1)/10)^2 – −1.318626
  ((Number of referrals+1)/10)^−2 – −0.015522
  ((Number of 
referrals+1)/10)^−2*ln((number of 
referrals+1)/10)
– −0.005468
  ((Number of consultations+1)/1000)^−0.5 – −0.171643
  ((Number of 
consultations+1)/1000)^−0.5*ln((number 
of consultations+1)/1000)
– −0.017409
Continued
individual prognosis or diagnosis (TRIPOD) guidelines (online 
supplementary file 2).30
resulTs
study population
Table 1 summarises the baseline characteristics of the study 
populations, showing broadly similar characteristics between 
THR and TKR cohorts.
Model development
Of 45 candidate categorical predictors of primary THR, 26 were 
excluded due to multivariable −1%≤PAR≤1% (online supple-
mentary table S2). Of the remaining 19 categorical predictors 
and 6 continuous predictors considered for inclusion in the 
multivariable prediction model, 14 categorical predictors and 6 
continuous predictors were retained after backward elimination 
(table 2). Previous hip injury recorded within 3 years prior to 
index consultation was a strong predictor of increased risk of 
future primary THR (adjusted subdistribution HR 1.54, 95% 
CI 1.40 to 1.69). Age at index consultation and body mass 
index (BMI) showed non-linear adjusted associations with THR, 
peaking at 75 years and 47 kg/m2 respectively (online supple-
mentary figure S7).
Of 53 candidate categorical predictors of primary TKR, 20 
were excluded due to multivariable −1%≤PAR≤1% (online 
supplementary table S3). Of the remaining 33 categorical predic-
tors and 6 continuous predictors entered into the multivariable 
prediction model, 19 categorical predictors and 5 continuous 
predictors were retained after backward elimination (table 2). 
Oral NSAID and opioid analgesic prescriptions, intra-articular 
injections and previous arthroscopic knee surgery in the 3 years 
prior to index consultation were strong predictors of increased 
risk of future primary TKR. Age and BMI showed non-linear 
adjusted associations, peaking at 70 years and 40 kg/m2 respec-
tively (online supplementary figure S8).
Apparent predictive performance of the models
Our final THR prediction model was able to discriminate 
between patients with and without a primary THR with a C-sta-
tistic of 0.73 (95% CI 0.72 to 0.73); our final TKR prediction 
model was also able to discriminate between patients with and 
without TKR with a C-statistic of 0.79 (0.78 to 0.79) over the 
10-year follow-up period. The calibration slope was 1.00 (0.98 
to 1.02) and 1.00 (0.99 to 1.01) for THR and THR, respectively, 
as we would expect.
Internal–external cross-validation
The internal-external cross-validation revealed that the C-sta-
tistic was similar in each of the 13 geographical regions, ranging 
from 0.70 (0.68 to 0.72) to 0.74 (0.73 to 0.75) for the THR 
model (figure 1 left panel) and between 0.76 (0.73 to 0.79) and 
0.82 (0.80 to 0.84) for the TKR model (figure 1 right panel). 
After meta-analysis, the summary C-statistic was 0.72 (0.72 to 
0.73) for the THR model and 0.78 (0.77 to 0.80) for the TKR 
model. Based on the 95% prediction intervals, if the models 
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Predictor
subdistribution 
hazard ratio (95 CI)
beta 
coefficient
  ((Number of BNF chapters+1)/10)^−2 – 0.110533
  ((Number of BNF 
chapters+1)/10)^−2*ln((number of BNF 
chapters+1)/10)
– 0.046402
Final model for primary total knee replacement
  Gender: women vs men 0.87 (0.85 to 0.90) −0.136204
Ethnicity 
  White reference –
  Other ethnicity group 0.90 (0.75 to 1.08) −0.105427
  Not recorded 1.04 (1.01 to 1.08) 0.042038
Smoking status 
  Non-smoker/not recorded/ex-smoker reference –
  Light smoker 0.75 (0.64 to 0.89) −0.281159
  Moderate/heavy smoker 0.75 (0.71 to 0.80) −0.281584
Drinking status 
  Non-drinker/not recorded reference –
  Ex-drinker 1.13 (1.09 to 1.50) 0.126359
  Light drinker 1.21 (1.07 to 1.38) 0.192886
  Moderate drinker/heavy drinker 1.34 (1.19 to 1.50) 0.289711
  Asthma, yes vs no 1.07 (1.03 to 1.12) 0.070898
  COPD, yes vs no 0.71 (0.66 to 0.77) −0.341224
  Diabetes mellitus: yes vs no 0.88 (0.84 to 0.93) −0.126142
Mental disorders: yes vs no 
  Anxiety 0.76 (0.73 to 0.80) −0.268390
  Depression 0.85 (0.81, 0.89) −0.164173
  Previous knee injury: yes vs no 1.29 (1.24 to 1.35) 0.256978
Recorded diagnosis of joint-specific OA 
  No/not recorded reference –
  Hip OA 0.59 (0.55 to 0.63) −0.528500
  Hand OA 0.61 (0.56 to 0.68) −0.486247
  Generalised OA/ 0.76 (0.69 to 0.83) −0.278839
  Other joint OA 0.74 (0.69 to 0.80) −0.296179
  Recorded diagnosis of non-specific OA: yes 
vs no
1.17 (1.12 to 1.22) 0.159204
  Low back pain: yes vs no 0.87 (0.84 to 0.90) −0.142815
  Hypertension: yes vs no 0.96 (0.93 to 0.99) −0.043010
  Joint injection: yes vs no 1.66 (1.60 to 1.72) 0.504619
  Knee arthroscopy: yes vs no 14.47 (13.95 to 15.02) 2.672150
  Antidepressant: yes vs no 0.95 (0.91 to 0.98) −0.054225
Analgesics 
  No prescription reference –
  Weak combination opioids 1.33 (1.27 to 1.39) 0.286170
  Moderate combination opioids 1.37 (1.22 to 1.54) 0.318097
  Strong/very strong combination opioids 1.59 (1.45 to 1.75) 0.465081
Topical NSAIDS 
  No prescription reference –
  NSAIDS 0.93 (0.90 to 0.96) −0.074381
  Other 1.17 (1.08 to 1.28) 0.160424
NSAIDS/COX2 
  No prescription reference –
  NSAIDS 1.41 (1.35 to 1.48) 0.343065
  COX2 1.27 (1.19 to 1.36) 0.238566
  (Age/10)^3 – 0.029250
  (Age/10)^3*ln(age/10) – −0.013246
  (BMI/10)^2 – 0.280906
  (BMI/10)^3 – −0.047226
Table 2 Continued
Continued
Predictor
subdistribution 
hazard ratio (95 CI)
beta 
coefficient
  ((Charlson comorbidity index+1)/10)^−2 – 0.002381
  ((Charlson comorbidity index+1)/10)^2 – −1.442397
  ((Number of referrals+1)/10)^−2 – −0.010564
  ((Number of 
referrals+1)/10)^−2*ln((number of 
referrals+1)/10)
– −0.002929
  ((Number of consultations+1)/1000)^−0.5 – −0.542288
  ((Number of 
consultations+1)/1000)^−0.5*ln((number 
of consultations+1)/1000)
– −0.073453
BNF, British National Formulary; COPD, chronic obstructive pulmonary disease; 
COX2, cyclooxygenase-2; NSAIDS, steroidal anti-inflammatory drugs.
Table 2 Continued
were applied in a new (but similar) setting, we would expect the 
C-statistic to be between 0.70 and 0.75 for the THR model and 
between 0.75 and 0.82 for the TKR model.
The calibration slope was also similar across the 13 regions, 
ranging between 0.93 (0.87 to 1.00) and 1.07 (1.01 to 1.13) 
for THR model (figure 2 left panel) and between 0.92 (0.90 
to 0.95) and 1.12 (1.05 to 1.19) for TKR model (figure 2 right 
panel). After meta-analysis, the summary calibration slope was 
1.00 (0.97 to 1.02) for the THR model and 1.01 (0.98 to 1.04) 
for the TKR model. If the models were applied in a new (but 
similar) setting, we would expect the calibration slope to be 
between 0.94 and 1.05 for the THR model and between 0.98 
and 1.12 for the TKR model.
The calibration plot in each validation cohort was presented 
for one imputed dataset, but comparable to the calibration plots 
in the other imputations (figure 3 for THR and in figure 4 for 
TKR). Good agreement between observed and predicted risks 
was observed in each geographical region cohort for THR. For 
those at highest risk of TKR (>10th decile), the observed risk 
was slightly higher than the predicted risk from the model in 
Northern Ireland, Scotland and Wales. We hypothesised that this 
slight miscalibration could result from systematic differences 
between these devolved nations and the English regions in the 
entry year or follow-up duration. However, on inspection, this 
was not the case (online supplementary figures S9 and S10).
The sensitivity analysis including patients with early outcomes 
(THR/TKR within 2 years of index consultation) gave similar 
levels of discrimination and calibration (online supplementary 
figure S11 and table S4). Similar model coefficients were derived 
by applying final predictors into patients with early outcomes 
(THR/TKR within 2 years of index consultation) (online supple-
mentary table S5).
Clinical examples
Online supplementary tables S6 and S7 give clinical examples 
of the application of THR and TKR risk prediction models to 
predict 10-year risk of THR and TKR, with examples chosen to 
illustrate ‘low’ and ‘high’ risk.
dIsCussIOn
We have developed and validated two algorithms to predict the 
absolute risk of future primary THR and TKR in patients who 
newly present to UK general practice with hip pain/osteoarthritis 
and knee pain/osteoarthritis. Internal–external cross-validation 
showed consistently good calibration when models are applied 
to the different geographical regions, and the models have good 
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Figure 1 C-statistics in 13 validation cohorts and the overall estimation across validation cohorts. The left panel is for THR model and the right is for 
TKR model.
Figure 2 Calibration slope in 13 validation cohorts and the overall estimation across validation cohorts. The left panel is for THR model and the 
right is for TKR model.
discrimination with C-statistics of greater than 0.70 for both 
models. To our knowledge, these are the first such risk predic-
tion tools, for primary THR and TKR in osteoarthritis devel-
oped in large-scale cohort data.
strengths and limitations of study
Our study was based on a large, representative and contempo-
rary UK population with data obtained from a validated research 
database.19 Risk prediction tools relying on routinely collected 
primary care data are more readily implementable in primary 
care practice10, and this was an important motivation for our 
study design. Potential limitations include missing predictor data 
and known predictors that are not measured or recorded in the 
primary care EHR. Around 5% of cohort participants did not 
have a recorded value for BMI in the 3 years prior to index pain/
osteoarthritis consultation, but we found little difference in find-
ings between complete dataset and multiple imputed datasets. 
We assumed no consultation record of a morbidity or prescrip-
tion meant, there had been no such event within primary care. 
Although it is a fairly standard approach to use the most recent 
record for time-varying exposures that are likely to be gener-
ally stable, this approach might still be conservative (ie, under-
estimate the exposure–outcome association) to the extent that 
it misclassifies the exposure level relevant to the outcome (eg, 
lifetime cumulative exposure to smoking).
Primary THR and TKR are complex, multiply determined 
outcomes and can be considered as a composite measure of osteo-
arthritis progression, since these procedures are indicated for a 
combination of pain, functional disability, impact on quality of 
life, radiological changes and failed conservative treatment.36 Joint 
replacement is an important outcome of osteoarthritis, and this is 
reflected in its role when judging the validity of imaging-related 
primary endpoints for clinical trials of structure-modifying drugs.37 
However, it is important to recognise that a proportion of indi-
viduals with progressive OA may not be offered, or accept, TKR/
THR. The receipt of TKR/THR can also reflect extraneous factors 
such as patient age, sex, ethnicity, willingness to undergo surgery, 
comorbidity, patients’ needs, patients’ coping skills, physician effect 
and prevailing supply-side factors.38 We found adjusted rates of 
THR and TKR were lower given the following patient characteris-
tics at or before index hip/knee consultation: age over 80–85 years, 
non-white ethnicity,39 higher levels of comorbidity (including diag-
nosed mental health disorder, generalised OA and low back pain) 
and very high levels of obesity. Osteoarthritis progression in the 
context of these factors will be underestimated by risk algorithms 
based on the outcome of receipt of primary joint replacement.
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Figure 3 Assessment of calibration for model predicting 10-year risk of primary total hip replacement in validation cohorts.
Figure 4 Assessment of calibration for model predicting 10-year risk of primary total knee replacement in validation cohorts.
A strength of our study was the comprehensive identification 
of candidate predictors from a variety of sources including a 
novel hypothesis-free ‘ReWAS’ study with replication in an inde-
pendent primary care EHR dataset. This latter technique yielded 
a small number of candidate predictors not previously reported 
(eg, arthroscopy). ReWAS also confirmed known prognostic 
factors or suggested prognostic factors that were most likely 
proxy markers for known predictors not obtainable from the 
EHR (eg, analgesic prescriptions as a proxy for pain severity). 
All such ‘hits’ had to be judged clinically relevant by review 
panel of clinicians and lay member in order to be included in 
the modelling stage. Unsurprisingly, many candidate predictors 
of future primary THR or TKR previously identified in the 
literature were not routinely available within the primary care 
record. These included multi-item patient-reported measures of 
pain severity,40 41 structural disease markers from plain X-rays or 
MRI40 42 and measures of occupational and leisure time physical 
activity.43–46 It is not known if their inclusion would significantly 
improve model performance.
Comparison with other studies
The majority of relevant previous studies have focused on one or 
more potential causal exposures for future joint replacement. We 
identified only three small studies that had previously derived 
and reported a multivariable prediction model for total hip or 
knee replacement based mainly on patient-reported and imaging 
variables.40 41 47 Although the overall performance of the prog-
nostic model is of primary importance, the direction and magni-
tude of association between some of the included predictors and 
outcome deserves comment. It must be recognised though that 
these associations are not intended to be, and cannot be inter-
preted as, valid estimates of causal effect (total, direct or indi-
rect) on primary hip/knee replacement: they are chosen for their 
informativeness in predicting primary THR/TKR. They may 
or may not be causal or reversible; all associations were condi-
tioned on having an index consultation for hip or knee osteo-
arthritis/pain; each coefficient was adjusted for all covariates in 
the model, but the minimally sufficient set of covariates needed 
to adjust for confounding would likely differ for each (the 
‘table 2 fallacy’48). With these concerns in mind, we note that 
adjusted rates of THR and TKR were lower among moderate/
heavy current smokers49 and higher among those with a previous 
injury.50 Prior arthroscopic knee surgery was strongly associ-
ated with future TKR, an association which may include a very 
small direct causal effect51 but which otherwise we interpret as 
reflecting a mixture of disease severity, risk of future progression 
and willingness to undergo a surgical procedure for the knee.
Implications
Our newly developed risk algorithms could have important 
applications in clinical practice by helping direct annual 
monitoring, intensive non-surgical care and timely assess-
ment and discussion of the need for surgical referral to those 
most at risk of progression. The algorithms can specifically 
identify the individuals who, in the context of current health-
care policies and resources, are at higher risk of future joint 
replacement, and therefore can be targeted for individual care 
ranging from earlier surgery to non-invasive care that might 
postpone the need for surgery. The hypothetical higher risk 
individual illustrated in online supplementary table S6 and 
S7 might, for instance, be targeted for a programme of more 
intensive multimodal therapy including graded supervised 
exercise and supported weight loss. The algorithm also uses 
future joint replacement as a proxy for future progression of 
osteoarthritis, and therefore potentially attempting to iden-
tify individuals more broadly who can be targeted for more 
intensive monitoring and interventions that might prevent 
such future progressions and severity regardless of whether 
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they would actually have had a joint replacement. For each of 
these clinical activities, a more targeted approach based on risk 
of progression may help. Monitoring of patients with osteo-
arthritis for progression of symptoms and impact is regarded 
as an important aspect of quality of care,52 but current The 
National Institute for Health and Care Excellence guidance 
would result in this being applied to a very large number of 
patients.53 Consideration for joint replacement should only 
be made after proper conservative care.3 While consistent 
evidence supports the effectiveness for knee OA of supervised, 
individually tailored exercise programmes progressed over 
several visits,6 many patients do not receive this52 partly due to 
limited physiotherapy resource8 and lack of referral.7 For many 
patients, joint replacement will still be the most cost-effective 
intervention and an earlier recognition of patients’ risk of 
future joint replacement may facilitate more timely assessment 
and discussion of appropriateness for referral. However, we 
caution against over-reliance on these risk algorithms, particu-
larly for individuals whose characteristics mean that they will 
not be candidates for surgery despite experiencing progressive 
disease, and against their crude application to ration what are 
highly cost-effective procedures of primary THR and TKR for 
osteoarthritis.
Conclusions
We have developed and validated two new risk prediction equa-
tions to quantify the absolute risks of primary THR and TKR in 
patients’ newly presenting with hip pain/OA or knee pain/OA in 
the primary care setting. The models have the advantage of being 
based on information routinely available in UK primary care 
EHR, making them potentially implementable for automatic 
risk calculation in electronic medical record software. They 
can be used to identify patients at high risk of end-stage OA for 
further assessments and intensive non-surgical intervention. The 
algorithms are readily amenable to further external validation in 
many developed countries that have routine records available for 
research. Further research is warranted to evaluate the clinical 
outcomes and cost effectiveness of using these risk equations in 
primary care.
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